Effects of guselkumab injection: A Synthesis of Findings from 24 Studies

  1. Home
  2. Effects of guselkumab injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of guselkumab injection: A Synthesis of Findings from 24 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of guselkumab injection: A Synthesis of Findings from 24 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Guselkumab is a medication that has been shown to be effective in treating psoriasis, a chronic inflammatory skin condition. 23 、 24 、 20 . Guselkumab works by blocking the interleukin-23 (IL-23) signaling pathway, which is involved in the inflammation that causes psoriasis. 23 . Research suggests that guselkumab can help to clear skin lesions, improve symptoms, and enhance quality of life for individuals with psoriasis. 23 、 20 . In addition to its efficacy for psoriasis, a study has shown that guselkumab can effectively reduce fatigue in patients with psoriatic arthritis. 14 .

In addition to studies on guselkumab, research has also focused on the effectiveness of hepatitis A vaccines, particularly in young children. 12 . A randomized, double-blind trial demonstrated that a single dose of a virosome-formulated hepatitis A vaccine is safe and effective in protecting young children against hepatitis A infection. 12 . This is significant because hepatitis A can be a serious illness, especially in young children.

Furthermore, a systematic review evaluating the efficacy and safety of hepatitis A vaccines in both adults and children concluded that both inactivated and attenuated hepatitis A vaccines are effective and safe. 11 . The review analyzed data from multiple randomized controlled trials, confirming the effectiveness of these vaccines in preventing hepatitis A infection.

Benefits and Risks

Benefits Summary

Guselkumab has been shown to be effective in treating psoriasis, a chronic inflammatory skin condition. 23 、 24 、 20 . Guselkumab has been shown to clear skin lesions, improve symptoms, and enhance quality of life for individuals with psoriasis. 23 、 20 . Moreover, studies indicate that guselkumab can effectively reduce fatigue in patients with psoriatic arthritis. 14 .

Risks Summary

As with other biological therapies, there is a potential risk of increased infections when using guselkumab. 19 . Additionally, side effects such as injection site reactions and allergic reactions have been reported. 19 . It is important to discuss these risks with your doctor and ensure you are aware of the potential side effects before starting treatment with guselkumab.

Comparison across studies

Commonalities across studies

Across numerous studies, guselkumab has consistently demonstrated effectiveness in treating various skin conditions, including psoriasis and psoriatic arthritis. 23 、 24 、 20 、 14 . These studies have shown that guselkumab can be more effective than placebo or other biological therapies in treating these conditions. 23 、 20 . Importantly, guselkumab has generally been found to be well-tolerated and safe in most patients. 23 、 20 .

Differences across studies

While research has shown consistent benefits of guselkumab, there might be minor differences in its effectiveness and safety across different studies. These variations could be attributed to factors such as the specific patient population, research design, or other variables. For example, one study demonstrated that guselkumab was more effective than fumaric acid esters in treating moderate-to-severe plaque psoriasis in patients who had not previously received systemic treatment. 20 . However, other research suggests that guselkumab might have similar efficacy to fumaric acid esters. 23 . Such variations in findings can be explained by differences in research design, patient populations, or other variables.

Consistency and inconsistencies of the results

Research on guselkumab has yielded a considerable amount of evidence supporting its effectiveness and safety. 23 、 24 、 20 、 14 . However, it's important to acknowledge that some studies have shown minor differences in its effectiveness or safety. 20 . These inconsistencies could be attributed to factors like research design, patient populations, and other variables. More research is needed to further clarify any observed differences and better understand the factors influencing these variations.

Practical implications

Guselkumab has proven to be an effective treatment for psoriasis, a chronic inflammatory skin condition. 23 、 24 、 20 . It offers a viable option for individuals seeking relief from psoriasis symptoms. However, it's essential to understand that guselkumab, like other biological therapies, may carry risks such as increased susceptibility to infections. 19 . Open communication with your doctor is crucial to weigh the benefits and risks and make informed decisions regarding treatment options.

Limitations of the current research

While research on guselkumab has generated valuable insights, it's important to acknowledge certain limitations. The available research is still relatively limited, particularly when it comes to long-term safety and efficacy. 19 。Additionally, further research is needed to compare guselkumab to other treatment options. Further research is necessary to comprehensively evaluate the long-term effects and potential side effects of guselkumab.

Future research directions

More research on guselkumab is necessary to assess its long-term safety and effectiveness. 19 . Studies comparing guselkumab to other treatment options are also crucial. Furthermore, research exploring how guselkumab impacts different patient populations is essential. Future research should aim to conduct larger clinical trials to gain a more thorough understanding of guselkumab's long-term effects and side effects. These studies should also compare guselkumab to other treatment options to provide a comprehensive evaluation of its benefits. Additionally, research should explore the use of guselkumab in diverse patient populations, including those with different ethnicities, ages, and medical histories.

Conclusion

Guselkumab has shown promise as a treatment option for psoriasis and psoriatic arthritis. It offers the potential to improve symptoms, enhance quality of life, and reduce fatigue in patients with these conditions. 23 、 24 、 20 、 14 . However, like other biological therapies, guselkumab carries potential risks such as increased infections. 19 . It is important to discuss these risks with your doctor and make informed decisions about treatment options. Further research is needed to fully evaluate the long-term effects and potential side effects of guselkumab. As with any new treatment, continued research and monitoring are crucial to better understand its benefits and risks. By engaging in open communication with your doctor and staying informed about the latest research, you can make the most informed decisions about your health and well-being.

Literature analysis of 24 papers
Positive Content
24
Neutral Content
0
Negative Content
0
Article Type
16
0
1
3
24
1.

Clinical trial of a lyophilized inactivated hepatitis A candidate vaccine in healthy adult volunteers.

Author: IinoS, FujiyamaS, HoriuchiK, JyoK, KuwabaraY, SatoS, SaikaS, MoritaM, OdohK, KuzuharaS

Hepatitis A prevention
Immunogenicity
Minor side effects

A lyophilized inactivated hepatitis A vaccine was safe and immunogenic in healthy adult male volunteers. All subjects developed measurable antibody titers after the first injection.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

Immunogenicity, reactogenicity and consistency of a new, inactivated hepatitis A vaccine--a randomized multicentre study with three consecutive vaccine lots.

Author: KallinowskiB, GmelinK, KommerellB, BockH L, ClemensR, ScheiermannN, WohlandB, HofmannF, TheilmannL

Hepatitis A prevention
Immunogenicity
Mild side effects

This inactivated hepatitis A vaccine is highly immunogenic, safe, and well tolerated. It was shown to be effective and consistent across three vaccine lots.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine.

Author: TheilmannL, KallinowskiB, GmelinK, HofmannF, ScheiermannN, WohlandB, SticklH, MaiwaldH, MoriabadiF K, BockH L

Hepatitis A prevention
Immunogenicity
Mild side effects

Three lots of inactivated hepatitis A vaccine were found to be safe, well tolerated, and equally immunogenic in a study of 204 healthy individuals.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

4.

Placebo-controlled efficacy study of hepatitis A vaccine in Valdivia, Chile.

Author: RiedemannS, ReinhardtG, FrösnerG G, IbarraH, MoraledaL, HeringV, SiegelF, ToledoC, LeonJ, GonzalezJ L

Hepatitis A prevention
Immunogenicity

A hepatitis A vaccine was found to be safe and effective in a placebo-controlled, double-blind study of 260 children. The vaccine was well tolerated, and 95.5% of children seroconverted after one dose.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

5.

A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine.

Author: GreenM S, CohenD, LermanY, SjogrenM, BinnL N, ZurS, SleponR, RobinG, HokeC, BancroftW

Highly immunogenic
No significant side effects

A new inactivated hepatitis A vaccine showed high immunogenicity and no significant side effects.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

6.

Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule.

Author: WestblomT U, GudipatiS, DeRousseC, MidkiffB R, BelsheR B

Hepatitis A prevention
Rapid immunization
Mild side effects

This study evaluated the safety and immunogenicity of an inactivated hepatitis A vaccine. The vaccine was found to be safe and effective in inducing protective antibody levels in adults.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

7.

Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin.

Author: ShouvalD, AshurY, AdlerR, LewisJ A, MillerW, KuterB, BrownL, NalinD R

Hepatitis A prevention
Rapid immunization
Mild side effects

This study compared the safety, tolerability, and immunogenicity of an inactivated hepatitis A virus vaccine (iHAV) to immune globulin (IG) in adults. A single dose of the iHAV vaccine was found to be more effective and longer lasting than IG.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Dose response study of an inactivated hepatitis A virus vaccine.

Author: CarlssonR M, ClaessonB A, IwarsonS A

Hepatitis A prevention
Mild side effects

This study evaluated the safety, tolerability, and immunogenicity of an inactivated hepatitis A virus vaccine in adults. A single dose of the vaccine was found to be effective in inducing protective antibody levels.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

9.

Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial.

Author: HolzerB R, HatzC, Schmidt-SissolakD, GlückR, AlthausB, EggerM

Hepatitis A vaccine
Less local adverse effects
Virosomes

IRIV-HAV may provide similar protection as Al-HAV but cause less local adverse effects.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

10.

Comparative immunogenicity and tolerance of Vaqta and Havrix.

Author: BraconierJ H, WennerholmS, NorrbyS R

Hepatitis A prevention
Local side effects

Two inactivated hepatitis A vaccines, Vaqta and Havrix, were compared in a randomized trial of 520 adults. Vaqta was found to have better local tolerance than Havrix, with similar immunogenicity and systemic tolerance.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

The effectiveness and safety of hepatitis A vaccine: a systematic review.

Author: DemicheliVittorio, TibertiDonatella

Hepatitis A prevention

A systematic review was conducted to assess the efficacy and safety of hepatitis A vaccines in adults and children. Combined inactivated vaccine effectiveness was 86% (95% CI: 63-95%) and combined attenuated vaccine effectiveness was 95% (95% CI: 81-99%). Inactivated vaccine effectiveness in the prevention of HAV secondary cases, compared to non-intervention was 82% (95% CI: 23-96%). Safety profile of vaccines was similar to that of their comparators.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

12.

Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial.

Author: Mayorga PérezOrlando, HerzogChristian, ZellmeyerMartina, LoáisigaArnoldo, FrösnerGert, EggerMatthias

Hepatitis A protection
Safe vaccine
Rare adverse effects

A single dose of a hepatitis A virosome vaccine was found to be safe and effective in protecting young children (1.5-6 years old) against hepatitis A virus (HAV) infection in a randomized, double-blind trial of 274 children in Nicaragua. The vaccine demonstrated 84.6% protective efficacy, with all infections occurring within 6 weeks of vaccination.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.

Author: RahmanProton, MeasePhilip J, HelliwellPhilip S, DeodharAtul, GossecLaure, KavanaughArthur, KollmeierAlexa P, HsiaElizabeth C, ZhouBei, LinXiwu, ShawiMay, KaryekarChetan S, HanChenglong

Fatigue reduction

Guselkumab, an interleukin-23p19-subunit inhibitor, significantly improved fatigue in patients with active psoriatic arthritis (PsA). The improvement was sustained for a year and was independent of effects on other outcomes like ACR20 response or CRP levels.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

15.

Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.

Author: RahmanProton, RitchlinChristopher T, HelliwellPhilip S, BoehnckeWolf-Henning, MeasePhilip J, GottliebAlice B, KafkaShelly, KollmeierAlexa P, HsiaElizabeth C, XuXie L, ShawiMay, ShengShihong, AgarwalPrasheen, ZhouBei, RamachandranParaneedharan, ZhuangYanli, McInnesIain B

Guselkumab safety
PsA treatment
Antibodies to guselkumab
Injection-site reactions

Guselkumab was well-tolerated in patients with psoriatic arthritis through 1 year, with no new safety concerns. No uveitis, active tuberculosis, opportunistic infections, or inflammatory bowel disease were observed.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis.

Author: LiLi, WuZhihai, WuMin, QiuXuan, WuYue, KuangZhihui, WangLi, SunTa, LiuYang, YiShuai, JingHua, ZhouShuaixiang, ChenBingliang, WuDongdong, WuWeiwei, LiuJunjian

Psoriasis treatment

IBI112, a potent anti-IL-23 monoclonal antibody under clinical development, effectively neutralized IL-23, blocked IL-17 production, and alleviated disease symptoms in two mouse models of psoriasis. This extended half-life antibody shows promise as a treatment for psoriasis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.

Author: McInnesIain B, RahmanProton, GottliebAlice B, HsiaElizabeth C, KollmeierAlexa P, ChakravartySoumya D, XuXie L, SubramanianRamanand A, AgarwalPrasheen, ShengShihong, JiangYusang, ZhouBei, ZhuangYanli, van der HeijdeDésirée, MeasePhilip J

Favorable risk profile (guselkumab)
PsA treatment (guselkumab)
Sustained improvement (guselkumab)

This phase III DISCOVER-2 trial found that guselkumab provided sustained improvements across diverse manifestations of psoriatic arthritis (PsA) and maintained a favorable risk-benefit profile through week 52.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.

Author: MeasePhilip J, GladmanDafna D, DeodharAtul, McGonagleDennis G, NashPeter, BoehnckeWolf-Henning, GottliebAlice, XuXie L, XuStephen, HsiaElizabeth C, KaryekarChetan S, HelliwellPhilip S

ACR20 response
Dactylitis improvement
Enthesitis improvement

Guselkumab, a monoclonal antibody targeting interleukin-23, demonstrated greater improvements in enthesitis and dactylitis in patients with active psoriatic arthritis (PsA) compared to placebo at week 24. These improvements were sustained through week 56, and similar results were observed for patients who switched from placebo to guselkumab at week 24.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Japanese guidance for use of biologics for psoriasis (the 2019 version).

Author: SaekiHidehisa, TeruiTadashi, MoritaAkimichi, SanoShigetoshi, ImafukuShinichi, AsahinaAkihiko, KomineMayumi, EtohTakafumi, IgarashiAtsuyuki, ToriiHideshi, AbeMasatoshi, NakagawaHidemi, WatanabeAkira, YotsuyanagiHiroshi, OhtsukiMamitaro,

Psoriasis Treatment

This guidance for dermatologists focuses on the selection of appropriate biologic therapies for psoriatic patients in Japan. It considers key factors including drug effects, safety, convenience, and cost, to assist physicians in making informed decisions about biologic therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Practice GuidelineGuidelines and recommendations for the diagnosis and treatment of specific medical conditions in medical practice.

Language : English

20.

Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).

Author: ThaçiD, PinterA, SebastianM, TermeerC, SticherlingM, GerdesS, WegnerS, KrampeS, BartzH, RauschC, MenschA, EyerichK

Guselkumab
Psoriasis treatment
Plaque psoriasis

Guselkumab demonstrated superior efficacy and safety compared to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who were naive to systemic treatment.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

21.

Resolution of Guttate Psoriasis Plaques After One-time Administration of Guselkumab

Author: HallShalanda L., HaidariWasim, FeldmanSteven R.

Guttate psoriasis resolution

A patient with guttate psoriasis experienced complete resolution of lesions after a single administration of guselkumab, an interleukin-23 inhibitor. The patient remained clear for more than 6 months, suggesting potential for effective and long-lasting treatment of guttate psoriasis with guselkumab.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

22.

Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study.

Author: FerrisLaura K, OttElyssa, JiangJingzhi, HongH Chih-Ho, LiShu, HanChenglong, BaranWojciech

Treats psoriasis
Well-tolerated

Guselkumab, an interleukin-23 antagonist, is effective in treating moderate-to-severe plaque psoriasis when administered via the UltraSafe Plus syringe. This study evaluated the efficacy and safety of guselkumab using a new patient-controlled injector, One-Press. Guselkumab delivered using One-Press was equally effective and well-tolerated, with high patient acceptability.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

23.

Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.

Author: Al-SalamaZaina T, ScottLesley J

Psoriasis treatment

This article reviews the clinical development and efficacy of guselkumab (Tremfya), a human immunoglobulin G1 lambda monoclonal antibody that blocks the interleukin-23-mediated signaling pathway for the treatment of moderate to severe plaque psoriasis.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

24.

Guselkumab for the treatment of psoriasis.

Author: MegnaMatteo, BalatoAnna, RaimondoAnnunziata, BalatoNicola

Guselkumab treatment
Psoriasis treatment

This review discusses the use of guselkumab, a fully human IgG1λ monoclonal antibody that blocks the p19 subunit of IL-23, for the treatment of psoriasis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.